Clinical trials: Resistant Depression, Treatment
Depressive Disorder, Treatment-Resistant
Epidemiology of Treatment Resistant Depression in Taiwan
The purpose of this study is to assess the epidemiology of Treatment Resistant Depression (TRD) in the nationally insured population in Taiwan including incidence, duration of clinical episodes, and prevalence by age and sex.
- Trial name
- NCT02691520
- Volunteers
- 8,356 people
- Sponsor
- Janssen Research & Development, LLC
Depression, Depressive Disorder, Treatment-Resistant
Improving Brain Stimulation Through Imaging
There are two protocols, one involving rTMS therapy in people with treatment resistant depression and one involving tDCS in people with stress from the COVID 19 pandemic.
- Conditions
- Depression, Depressive Disorder, Treatment-Resistant, COVID Stress, PTSD - Post Traumatic Stress Disorder
- Trial name
- IBSI (NCT03851380)
- Testing
- Psychological / Functional Assessment, Structural and Functional MRI, Transcranial Magnetic Brain Stimulation and MR Image Guidance
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- VA Office of Research and Development
Major Depression
Use of Risperidone in ECT for Treatment Resistant Depression
The purpose of this study is to determine if the combination of risperidone and ECT improves a patient's response in depression compared to ECT alone.
- Trial name
- NCT00203723
- Testing
- Risperidone
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of California, Los Angeles
Bipolar Disorder
Treatment Resistant Depression in Bipolar Disorder - A Randomized Controlled Trial of Electroconvulsive Therapy
This project is a randomized controlled trial of electroconvulsive therapy (ECT) compared to treatment as usual (TAU) in the treatment of treatment resistant depression (TRD) in bipolar disorder.
- Trial name
- NCT00664976
- Testing
- Electroconvulsive therapy, Treatment as usual
- Where
- 2 sites in Norway
- Volunteers
- 73 people
- Sponsor
- Norwegian University of Science and Technology
Major Depressive Disorder
Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Depression
The purpose of the study is to determine the efficacy, safety and pharmacokinetics of inhaled Esketamine in participants with treatment-resistant depression (TRD) in the course of Major Depressive Disorder (MDD).
- Trial name
- NCT03965858
- Testing
- Esketamine DPI - low dose, Esketamine DPI - medium dose, Esketamine DPI - high dose
- Where
- 12 sites in Poland
- Volunteers
- 88 people
- Sponsor
- Celon Pharma SA
Depression - Major Depressive Disorder, Depression Bipolar
Mental Health Mission Mood Disorder Cohort Study
The current study aims to understand why some people with depression respond to treatment and others do not, using markers of clinical symptoms, both clinician reported outcome measures and patient reported outcome measures…
- Conditions
- Depression - Major Depressive Disorder, Depression Bipolar, Treatment Resistant Depression
- Trial name
- NCT07189689
- Where
- United Kingdom
- Volunteers
- 2,000 people
- Sponsor
- University of Oxford
Treatment-resistant Depression
A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression
The purpose of this study is to compare the efficacy and safety of switching treatment-resistant depression (TRD) subjects from a prior antidepressant treatment (to which they have not responded) to either intranasal esketamine…
- Trial name
- TRANSFORM-2 (NCT02418585)
- Testing
- Esketamine, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant)
- Where
- 48 sites in United States, Czechia and 3 more
- Volunteers
- 236 people
- Sponsor
- Janssen Research & Development, LLC
Treatment Resistant Depression
Compressed Intermittent Theta Burst Stimulation
In this proposal the investigators will use an accelerated TMS protocol that concentrates the magnetic stimulation that would usually occur over 6 weeks into 10 treatment sessions per days, for 5 consecutive days in patient with…
- Trial name
- ciTBS (NCT04684706)
- Testing
- intermittent Theta Burst Stimulation
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- University of Pennsylvania
Depressive Disorder, Treatment-Resistant
A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression
The purpose of this study is to assess the safety and tolerability of esketamine nasal spray in participants with treatment-resistant depression (TRD).
- Trial name
- SUSTAIN-3 (NCT02782104)
- Testing
- Esketamine Nasal Spray
- Where
- 173 sites in United States, Argentina and 24 more
- Volunteers
- 1,148 people
- Sponsor
- Janssen Research & Development, LLC
Depression
Sequenced Treatment Alternatives to Relieve Depression (STAR*D)
STAR*D focuses on non-psychotic major depressive disorder in adults who are seen in outpatient settings. The primary purpose of this research study is to determine which treatments work best if the first treatment with medication…
- Trial name
- NCT00021528
- Testing
- citalopram, BuproprionSR, buspirone
- Where
- 41 sites in United States
- Volunteers
- 4,000 people
- Sponsor
- National Institute of Mental Health (NIMH)
Treatment Resistant Depression
Low Field Magnetic Stimulation for Treatment Resistant Depression
This is a double-blind, randomized, sham-controlled phase II study of the effects of Low Field Magnetic Stimulation (LFMS) on brain circuitry of adults with treatment-resistant Major Depressive Disorder (MDD).
- Trial name
- NCT01944644
- Testing
- Active Low Field Magnetic Stimulation
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Weill Medical College of Cornell University
Depressive Disorder, Major
Ketamine for Treatment Resistant MDD
This study aims to openly test the long-term safety, tolerability and effectiveness of repeated administration of IM/SC ketamine for treatment resistant MDD.
- Trial name
- NCT04021433
- Testing
- Ketamine
- Where
- Israel
- Volunteers
- 20 people
- Sponsor
- Hadassah Medical Organization
Treatment Resistant Depression, Treatment Resistant Depression (TRD)
A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Robotic Transcranial Magnetic Stimulation for Treatment Resistant Depression: The SPARC-TMS Trial
Major depressive disorder (MDD) is a significant public health problem and leading cause of worldwide disability. Treatment resistance is common in MDD, however, for these individuals, targeted noninvasive brain stimulation is an…
- Trial name
- SPARC-TMS (NCT07227103)
- Testing
- Neuronavigated robotic-enabled TMS, NRX-101
- Where
- 3 sites in United States
- Volunteers
- 240 people
- Sponsor
- NeuroRx, Inc.
Major Depressive Disorder, Depression
Investigating Predictors of Treatment Response in Treatment-Resistant Depression (TRD) With Interleaved TMS/fMRI
The purpose of this trial is identify biomarkers of response to repetitive transcranial magnetic stimulation (rTMS) in individuals with first episode or treatment resistant depression.
- Trial name
- NCT03642522
- Testing
- repetitive transcranial magnetic stimulation
- Where
- Canada
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Major Depression
Antidepressant Effects of Ayahuasca: a Randomized Placebo Controlled Trial in Treatment Resistant Depression
The purpose of the present trial is to test the efficacy of Ayahuasca in treatment-resistant depression. Ayahuasca is a decoction of two plants, long used by Amazonian Amerindians.
- Trial name
- NCT02914769
- Testing
- Ayahuasca
- Where
- Brazil
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Universidade Federal do Rio Grande do Norte
Major Depressive Disorder (MDD)
Accelerated Neuromodulation of Anterior Cingulate Cortex for Depression
The goal of this clinical trial is to test whether an accelerated deep Transcranial Magnetic Stimulation (dTMS) protocol can reduce depressive symptoms in older adults (ages 60-85) with Major Depressive Disorder (MDD) who have…
- Trial name
- NACC-D (NCT07212465)
- Testing
- Active Brainsway H7-Coil Deep TMS System
- Where
- Canada
- Volunteers
- 24 people
- Sponsor
- Rotman Research Institute at Baycrest
Depression - Major Depressive Disorder, Treatment-resistant Depression (TRD)
Efficacy of Psilocybin and Trazodone Combination in Treatment-resistant Depression: a Randomized Controlled Proof-of-concept Study (PSILOTRAZ)
Psilocybin, a serotonin receptor agonist in the brain, significantly and quickly improves depressive symptoms while inducing profound acute subjective effects.
- Trial name
- PSILOTRAZ (NCT07210112)
- Testing
- Psilocybin 25 mg per os, Trazodone 5mg, Trazodone 30 mg
- Where
- France
- Volunteers
- 112 people
- Sponsor
- Centre Hospitalier St Anne
Treatment Resistant Depression, Refractory Depression
Ketamine for Older Adults Pilot
This pilot study will assess the safety and feasibility of intravenous (IV) ketamine in older adults with Treatment-Resistant Depression (TRD).
- Conditions
- Treatment Resistant Depression, Refractory Depression, Therapy-Resistant Depression, Late Life Depression
- Trial name
- NCT04504175
- Testing
- Ketamine
- Where
- 5 sites in United States, Canada
- Volunteers
- 25 people
- Sponsor
- Washington University School of Medicine
Major Depressive Disorder, Insulin Resistance
Pioglitazone in Patients With Mood Disorders
The purpose of this study is to see how an insulin sensitizing medication, Pioglitazone, can cause changes in mood in some depressed patients. Study participants receive assessment of their cognitive and metabolic functioning.
- Trial name
- NCT01559857
- Testing
- Pioglitazone, Sugar Pill
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Stanford University
Major Depressive Disorder, Unipolar Depression
TBS Treatment for Treatment-Resistant Depression
Depression is a highly disabling disease that is prevalent throughout the world. The treatments proposed and studied to date have shown to be partially effective in treating this condition.
- Trial name
- TTT (NCT05388539)
- Testing
- Theta Burst Stimulation
- Where
- Brazil
- Volunteers
- 100 people
- Sponsor
- University of Sao Paulo